July 15, 2024
Looking ahead to one of our busiest weeks of the year: IAVI at the International AIDS Conference
IAVI leaders will present on why we still need an HIV vaccine and how to engage communities in clinical trials and will launch an Action Plan for accelerating progress on broadly neutralizing antibodies for HIV prevention.
IAVI is looking forward to a busy and exciting week at the International AIDS conference, taking place July 22-26 in Munich, Germany. IAVI leaders will participate in a range of sessions, including IAVI-organized satellite sessions, posters, a pre-conference session, and, of course, many side meetings. Some highlights of IAVI’s upcoming participation include:
- An IAVI and Brilliant Consortium co-hosted satellite session, Discovery medicine trials for HIV vaccines — identifying key lessons, challenges and opportunities for strengthening local preparedness and regional partnerships in Africa. This session will be co-chaired by Nigel Garrett of CAPRISA and IAVI’s Kundai Chinyenze, ADVANCE chief of party and IAVI Africa director. Please join us and our partners to learn more about how to strengthen local preparedness, and the critical role of strong regional partnerships for advancing discovery medicine trials. This session will take place July 22 at 9:30.
- An IAVI satellite session, How the biomedical should be informed by the social — navigating gaps and challenges in eliciting end-user perspectives towards informing next-generation HIV products, moderated by IAVI’s Ken Ondenge’e, manager, socio-behavioral research, and IAVI’s Paromita Saha, program manager, research and development, and with remarks from IAVI’s Yvonne Wangui Machira, director, socio-behavioral research, and IAVI’s Saif ul Hadi, director, access, India. Join us for an important conversation about how to integrate end-user perspective and preferences in designing biomedical products. This session will take place July 22 at 13:00.
- An IAVI-hosted satellite session, An Action Plan to accelerate bnAbs for peri- and post-natal prophylaxis (PNP). This session will launch an Action Plan outlining cross-cutting priority actions to accelerate development and availability of bnAbs for infant HIV prophylaxis, and will be moderated by Linda-Gail Bekker, CEO of the Desmond Tutu Health Foundation and IAVI’s Shelly Malhotra, vice president of global access and external affairs. It will also feature remarks from IAVI’s Vincent Muturi-Kioi, HIV vaccines product development lead, and USAID’s Lusine Ghazaryan, medical director, among other notable speakers. This session will take place July 24 at 18:00.
- An IAVI satellite session, Ending AIDS as a public health threat: the role of a vaccine in the era of long-acting PrEP, featuring remarks from IAVI’s president and CEO Mark Feinberg, NIAID Director Jeanne Marrazzo, among other distinguished panelists, and moderated by Linda-Gail Bekker, CEO of the Desmond Tutu Health Foundation and IAVI Board of Directors member. Please join us for a rich discussion on the continuing need and role of an HIV vaccine, even as we are on the cusp of promising HIV prevention progress from long-acting PrEP options. This session will take place July 25 at 18:00.
We welcome you to attend IAVI-hosted events throughout the week, whether you are in-person in Munich or participating in the IAS conference virtually. Check out the full calendar of events where IAVI leaders will speak. We are looking forward to seeing you in Munich.